Observed arrival · 2026-10-17
A radiation-oncology market proposal for Precision IO
Robert Draper makes a case for a proposed role taking Precision IO’s Epione robotic needle-placement system into radiation oncology.
○Open
⊠Login
$Paid
†Ads
✦Pretty
●Pro
◎Niche
◉Human
⚑Risk
ƒJS
- For
- Precision IO decision-makers considering a radiation-oncology role
- Worth noticing
- The page says Epione is FDA-cleared only for CT-guided abdominal ablation; radiation-oncology use would require an expanded indication.
Field notes
The proposal is organized as a short executive case, with a three-minute reading route through pages 02, 04, and 05 and a longer route that includes sources. Draper describes the role as exploratory rather than quota-driven and separates the proposed radiation-oncology market from Precision IO’s existing NeuWave business. The page labels its own hypotheses and states that Precision IO has not announced a radiation-oncology strategy.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
○OpenPublic substance visible
✦PrettyNotable craft visible
◎NicheUnusually specific use
◉HumanPersonal, local, civic, or handmade
One card from the complete issue